Arrowhead Research Corp. (ARWR) Shares Up 5.1%
Arrowhead Research Corp. (NASDAQ:ARWR)’s share price shot up 5.1% during mid-day trading on Tuesday . The company traded as high as $7.47 and last traded at $7.24, with a volume of 770,957 shares traded. The stock had previously closed at $6.89.
A number of research firms recently issued reports on ARWR. William Blair began coverage on shares of Arrowhead Research Corp. in a research report on Friday, August 19th. They set an “outperform” rating for the company. Cantor Fitzgerald assumed coverage on shares of Arrowhead Research Corp. in a research report on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price target for the company. Piper Jaffray Cos. decreased their price target on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. Chardan Capital assumed coverage on shares of Arrowhead Research Corp. in a research report on Thursday, May 19th. They issued a “buy” rating and a $12.00 price target for the company. Finally, Jefferies Group restated a “hold” rating and issued a $4.75 price target on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Arrowhead Research Corp. presently has an average rating of “Buy” and a consensus target price of $10.44.
The company’s 50 day moving average price is $6.24 and its 200-day moving average price is $5.51. The stock’s market cap is $421.00 million.
Arrowhead Research Corp. (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. The firm earned $39.58 million during the quarter, compared to the consensus estimate of $0.05 million. During the same quarter last year, the business posted ($0.27) earnings per share. Arrowhead Research Corp.’s revenue was down 68.0% compared to the same quarter last year. On average, equities research analysts anticipate that Arrowhead Research Corp. will post ($1.31) earnings per share for the current year.
In other news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the firm’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total value of $55,200.00. Following the completion of the transaction, the chief financial officer now directly owns 128,789 shares in the company, valued at $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.